Sara Caratelli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy.
Journal: Cancer cell international
Published: April 11, 2025
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity.
Journal: Experimental hematology & oncology
Published: October 30, 2024
Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.
Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.
Journal: Cancer cell international
Published: July 15, 2024
Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases.
Journal: Mechanisms of ageing and development
Published: February 14, 2023
Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Journal: Life science alliance
Published: July 04, 2022
Glioma extracellular vesicles for precision medicine: prognostic and theragnostic application.
Journal: Discover oncology
Published: April 07, 2022
In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Journal: International journal of cancer
Published: March 19, 2019
CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Journal: International journal of cancer
Published: March 14, 2019
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
Journal: Frontiers in immunology
Published: February 03, 2017
Last Updated: 09/26/2026